Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Possible. I don't trust him at all. He single handedly wiped out 30 mil mkt cap
Not necessarily. 8-K needs to come out for confirmation. All of the hush hush period could be a potential monster but you never know what could happen.
RS approved. Dead bird
If RS vote gets rejected which I think it will this should rally today. Vote results 11am eastern
News not helping the situation.
As of December 31, 2023, Virios Therapeutics’ cash totaled $3.3 million. The Company believes it has sufficient resources to fund operations into the fourth quarter of 2024.
The SPV of Operations just bought 62,568!! VIRI LONG💰
https://www.sec.gov/Archives/edgar/data/1818844/000141588924005670/xslF345X05/form4-02282024_050234.xml
The CMO just bought 88,085!! VIRI LONG💰
https://www.sec.gov/Archives/edgar/data/1818844/000141588924005668/xslF345X05/form4-02282024_050208.xml
Greg Duncan(CEO) just purchased 138,835 shares two days ago!! VIRI LONG💰
Pretty nice display of faith in the company here:
“On February 26, 2024, the Board of Directors (the “Board”) of Virios Therapeutics, Inc. (the “Company”) approved a 10% salary reduction for each employee of the Company, including each of the Company’s executive officers, effective March 1, 2024. In addition, on February 26, 2024, the Board approved a 10% reduction in the cash compensation of the non-employee members of the Board.”
There are only three dummy employees. That's the board clown. Prove me wrong! 🤡
IMC-2 Long-COVID Development Program: We have clarity from the Food and Drug Administration (“FDA”) on the development requirements for advancing IMC-2 (combination of valacyclovir and celecoxib) into Phase 2 development as a treatment for LC symptoms. As noted above, we expect to receive top line results from the ongoing Bateman Horne Center independent investigator supported study in the second half of 2024. There continues to remain a high unmet medical need for treating LC symptoms. Recently, a USA Today Health article reported that federal estimates suggest at least 16 million Americans have LC and as many as 4 million of them are disabled by it. There are currently no FDA approved LC treatments. We are excited that IMC-2 has the potential to be one of the first approved treatments for LC and are exploring various means by which to fund execution of the important Phase 2b IMC-2 trial.
IMC-1 Fibromyalgia Development Program: We reached alignment with the FDA on the IMC-1 (combination of famciclovir and celecoxib) Phase 3 development program for treatment of fibromyalgia. We continue to be engaged with potential external entities who have an interest in partnering for this important program.
The Virios team remains committed to delivering on the promise of combination antiviral therapy to address a multitude of serious health issues and illnesses. We appreciate your support.
February 27, 2024
Dear Virios (VIRI) Shareholders,
On behalf of the Virios directors and the executive team, we would like to provide a corporate progress report on several key topics as we proceed through the first quarter of 2024.
Special Shareholder Meeting: On March 1, 2024, we will hold a special shareholder meeting, whereby we are requesting your approval to execute a reverse stock split some time over the course of the next 12 months. In our outreach to shareholders in connection with the meeting, we heard concerns about whether and when the reverse stock split would be implemented, if approved, and we want to address those concerns here. Approval of this proposal does not commit the Company to the execution of a reverse stock split. It does provide maximum strategic optionality moving forward, including the ability to execute strategic transactions and to enable future fund raising.
Indeed, the Board’s unanimous view is that the implementation of the reverse stock split should be deferred until after the Company has clarity on the results of the current Long-COVID (“LC”) study being independently run via an unrestricted grant to the Bateman Horne Center. Results from this study are currently projected to be reported in the second half of 2024.
Director Fee and Management Team 10% Salary Cut: We work diligently to minimize operational expenses and deploy our cash to fund value creating research as evidenced by the fact that we operate VIRI as a public company with four full-time employees. In order to underscore the management team’s alignment as fellow shareholders and to emphasize our commitment to long-term success and value creation, all of Virios’ employees have agreed to a 10% salary compensation reduction in exchange for future vesting stock options. In addition, our directors have also agreed to a 10% reduction in cash director fees.
IMC-2 Long-COVID Development Program: We have clarity from the Food and Drug Administration (“FDA”) on the development requirements for advancing IMC-2 (combination of valacyclovir and celecoxib) into Phase 2 development as a treatment for LC symptoms. As noted above, we expect to receive top line results from the ongoing Bateman Horne Center independent investigator supported study in the second half of 2024. There continues to remain a high unmet medical need for treating LC symptoms. Recently, a USA Today Health article reported that federal estimates suggest at least 16 million Americans have LC and as many as 4 million of them are disabled by it. There are currently no FDA approved LC treatments. We are excited that IMC-2 has the potential to be one of the first approved treatments for LC and are exploring various means by which to fund execution of the important Phase 2b IMC-2 trial.
IMC-1 Fibromyalgia Development Program: We reached alignment with the FDA on the IMC-1 (combination of famciclovir and celecoxib) Phase 3 development program for treatment of fibromyalgia. We continue to be engaged with potential external entities who have an interest in partnering for this important program.
The Virios team remains committed to delivering on the promise of combination antiviral therapy to address a multitude of serious health issues and illnesses. We appreciate your support.
Employee Salary and Director Compensation Reduction
On February 26, 2024, the Board of Directors (the “Board”) of Virios Therapeutics, Inc. (the “Company”) approved a 10% salary reduction for each employee of the Company, including each of the Company’s executive officers, effective March 1, 2024. In addition, on February 26, 2024, the Board approved a 10% reduction in the cash compensation of the non-employee members of the Board.
Getting active on social media😎
It's clear that this represents a large unmet medical need.
— Virios Therapeutics (@ViriosBiotech) February 27, 2024
Millions of Americans suffer from long COVID. Why do treatments remain out of reach? https://t.co/kCYE7QImFB via @usatoday
Getting active on social media😎
It's clear that this represents a large unmet medical need.
— Virios Therapeutics (@ViriosBiotech) February 27, 2024
Millions of Americans suffer from long COVID. Why do treatments remain out of reach? https://t.co/kCYE7QImFB via @usatoday
These 30s may pay off if someone was a gambling type. Level 2 this morning is either a gap and trap, or it's going in to the 40s and above
Never gonna happen. Will never be approved. My guess is these POS fualks actually have a partnership lined up And will dump heavy into news just for fualks sake.
Voting NO on RS is requested from numerous large shareholders. If RS approved Greg will do a large offering afterwards to fund the trials instead of going the harder, yet company positive route of grants, partnerships. We cannot reward failure with RS to a CEO that only owns 60k shares. Vote NO RS and put his feet to the fire to produce organically.
What? This POS will pop to .60 whatever who cares
Greg took a hot shit in our mouths. Greg is a POS.
Why are you still here, then??
VIRI is dead until after the February vote. Dead money probably into summer.
Dude, you are here. Make sense?
Where are the clowns? HELLO?
You shut up clown you are a joke no one wants to hear your rambling incoherent nonsensical pumping BS with no company knowledge go sit down in the child table.
Why would these stupid fucks be buying shares in the +$1 range and then release bad news after bad news that was totally unnecessary? It makes no sense that Greg would put out the PR's and then retract doing toxic financing saying ohh it's ok we have money just kidding ohh wait we might partner no just kidding?
We see right through your BS. Bash, and then throw $18,000 BIDS up! Typical troll. VIRI LONG$$$$
💯. So disappointing. Fantastic pipeline..Ferrari with a woman driver🤣🤣
Yea it's like a chef owning a restaurant. I've seen it terrible.
Fact of the matter is Greg Duncan is really just that inept when it comes to running a public company. Scientists are terrible CEOs and Greg is the perfect example of that. Who puts out FDA news and then a 14a 30 minutes later with reverse split I mean to see that fucking stupid
The way the planned everything with the PR releases seems very suspect IMO. Especially how they correlated with the PPS. I feel somebody was making money illegally IMO.
I am voting no on everything. Just because he sucks
I'm sure it will be on our proxy vote.
I believe the biggest shareholders are calling for Greg to be terminated due to gross mismanagement. His blunders cost this company 45 million in market cap..
This my friend is TRUTH! I could not agree more and that is the day I turned.
Pumping, no pointing out FACTS, linking sources etc. Instead the bear crew including you just basically contribute nothing but stupid one liners. Please by the way you come across acting like you a turned long here but reality your probably just another paid to post negative crap on social media hired by a broker shorting
You're pumping day after day doesn't help either.
Followers
|
63
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
4183
|
Created
|
06/09/21
|
Type
|
Free
|
Moderators DavidLeeRoth |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |